✦ LIBER ✦

Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage–colony stimulating factor in patients with advanced pancreatic adenocarcinoma

✍ Scribed by Gabriela Kornek; Markus Raderer; Thomas Schenk; Johann Pidlich; Franz Schulz; Sebastian Globits; Christine Tetzner; Werner Scheithauer

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 659 KB
Volume: 76
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19951015)76:8<1356::aid-cncr2820760810>3.0.co;2-#

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Granulocyte-macrophage-colony stimulatin

Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma : A phase II trial

✍ Brian I. Rini; Walter M. Stadler; Ricardo T. Spielberger; Mark J. Ratain; Nichol 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## BACKGROUND. Due to lack of success with standard chemotherapy and only modest

Phase II trial of subcutaneously adminis

Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma

✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB 👁 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

A phase I trial of intraperitoneal carbo

A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies

✍ Edward F. McClay; Patricia D. Braly; Saeeda Kirmani; Steven C. Plaxe; Mary Eilee 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 580 KB

Intradermal ras peptide vaccination with

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma

✍ Marianne K. Gjertsen; Trond Buanes; Arne R. Rosseland; Arne Bakka; Ivar Gladhaug 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 263 KB

K-RAS mutations are frequently found in adenocarcinomas of the pancreas, and induction of immunity against mutant ras can therefore be of possible clinical benefit in patients with pancreatic cancer. We present data from a clinical phase I/II trial involving patients with adenocarcinoma of the pancr

A Phase I dose escalation of combination

A Phase I dose escalation of combination chemotherapy with granulocyte-macrophage–colony stimulating factor in patients with neuroblastoma

✍ M. Carmen Fernandez; Mark D. Krailo; Robert R. Gerbing; Katherine K. Matthay 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

Granulocyte-macrophage–colony stimulatin

Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f